Talis Biomedical Corporation
TLIS · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $4 | $0 | $11 |
| % Growth | -88.7% | – | -100% | – |
| Cost of Goods Sold | $0 | $8 | $3 | $1 |
| Gross Profit | $0 | -$5 | -$3 | $10 |
| % Margin | 90% | -129.8% | – | 87.4% |
| R&D Expenses | $41 | $71 | $158 | $89 |
| G&A Expenses | $0 | $0 | $0 | $13 |
| SG&A Expenses | $28 | $41 | $42 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | -$1 | -$3 | -$1 |
| Operating Expenses | $67 | $110 | $197 | $101 |
| Operating Income | -$67 | -$113 | -$200 | -$91 |
| % Margin | -16,217.2% | -3,086.1% | – | -833.6% |
| Other Income/Exp. Net | $5 | -$0 | $8 | $0 |
| Pre-Tax Income | -$62 | -$113 | -$192 | -$91 |
| Tax Expense | $0 | $0 | -$2 | -$0 |
| Net Income | -$62 | -$113 | -$190 | -$91 |
| % Margin | -15,050.2% | -3,094.5% | – | -832.7% |
| EPS | -34.12 | -63.65 | -126.13 | -314.06 |
| % Growth | 46.4% | 49.5% | 59.8% | – |
| EPS Diluted | -34.12 | -63.65 | -126.13 | -314.06 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 0 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $12 | $3 | $1 |
| EBITDA | -$66 | -$101 | -$189 | -$90 |
| % Margin | -16,030.3% | -2,776.9% | – | -820.6% |